top of page
Search
Kuria Therapeutics Awarded NIH/NEI SBIR Fast Track Phase I/II Grant to Advance IND-Enabling Toxicology Studies of SCO-116 for Corneal Endothelial Disease and Injury
Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.
Keith Ward
Sep 11
Seed Round Completed
Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator - Funds to support ongoing preclinical development...
Keith Ward
Sep 7, 2022
bottom of page